Risk of bleeding and stroke with oral anticoagulation and antiplatelet therapy in patients with atrial fibrillation in Taiwan: A nationwide cohort study

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Chen, Pei Chun ^a   Lip, Gregory Y H ^b   Yeh, Grace ^c   Lin, Hung Ju ^c,d   Chien, Kuo Liong ^c,d  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; PROPAFENONE; SOTALOL; WARFARIN;

AGE DISTRIBUTION; AGED; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CHINESE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; MEDICAL RECORD; MONOTHERAPY; NATIONAL HEALTH INSURANCE; PRESCRIPTION; SEX RATIO; TAIWAN; TREATMENT OUTCOME; CHEMICALLY INDUCED; FACTUAL DATABASE; HEMORRHAGE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RETROSPECTIVE STUDY; STROKE; VERY ELDERLY;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; DATABASES, FACTUAL; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; RETROSPECTIVE STUDIES; STROKE; TAIWAN;

EID: 84928795012     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0125257     Document Type: Article

References (36)

1. Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: The Swedish Atrial Fibrillation cohort study. Eur Heart J. 2012; 33: 1500-1510. doi:10.1093/eurheartj/ehr488 PMID: 22246443.
2. Lee CH, Liu PY, Tsai LM, Tsai WC, Ho MT, Chen JH, et al. Characteristics of hospitalized patients with atrial fibrillation in Taiwan: A nationwide observation. Am J Med. 2007; 120: 819 e811-817. PMID: 17765055.
3. Potpara TS, Lip GYH. Ischemic Stroke and Atrial Fibrillation-A DeadlySerious Combination. Cerebrovascular Diseases. 2011; 32: 461-462. doi:10.1159/000332030 PMID: 22005454.
4. Chien KL, Su TC, Hsu HC, Chang WT, Chen PC, Sung FC, et al. Constructing the prediction model for the risk of stroke in a Chinese population: report from a cohort study in Taiwan. Stroke. 2010; 41: 1858-1864. doi:10.1161/STROKEAHA.110.586222 PMID: 20671251.
5. Chien KL, Su TC, Hsu HC, Chang WT, Chen PC, Chen MF, et al. Atrial fibrillation prevalence, incidence and risk of stroke and all-cause death among Chinese. Int J Cardiol. 2010; 139: 173-180. doi:10.1016/j.ijcard.2008.10.045 PMID: 19046608.
6. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001; 285: 2864-2870. PMID: 11401607.
7. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The euro heart survey on atrial fibrillation. Chest. 2010; 137: 263-272. doi:10.1378/chest.09-1584 PMID: 19762550.
8. Lin LY, Lee CH, Yu CC, Tsai CT, Lai LP, Hwang JJ, et al. Risk factors and incidence of ischemic stroke in Taiwanese with nonvalvular atrial fibrillation-a nation wide database analysis. Atherosclerosis. 2011; 217: 292-295. doi:10.1016/j.atherosclerosis.2011.03.033 PMID: 21513938.
9. Friberg L, Benson L, Rosenqvist M, Lip GY. Assessment of female sex as a risk factor in atrial fibrillation in Sweden: nationwide retrospective cohort study. BMJ. 2012; 344: e3522. doi:10.1136/bmj.e3522 PMID: 22653980.
10. Olesen JB, Torp-Pedersen C, Hansen ML, Lip GY. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: A nationwide cohort study. Thromb Haemost 2012; 107: 1172-1179. doi:10.1160/TH12-03-0175 PMID: 22473219.
11. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: A meta-analysis. Ann Intern Med. 1999; 131: 492-501. PMID: 10507957.
12. Lip GY, Andreotti F, Fauchier L, Huber K, Hylek E, Knight E. Executive Summary of a Position Document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis. Thromb Haemost. 2011; 106: 997-1011. doi:10.1160/TH11-10-0690 PMID: 22048796.
13. Hansen ML, Sørensen R, Clausen MT, Fog-Petersen ML, Raunsø J, Gadsbøll N, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med. 2010; 170: 1433-1441. doi:10.1001/archinternmed.2010.271 PMID: 20837828.
14. Röther J, Crijns H. Prevention of Stroke in Patients with Atrial Fibrillation: The Role of New Antiarrhythmic and Antithrombotic Drugs. Cerebrovascular Diseases. 2010; 30: 314-322. doi:10.1159/000319608 PMID: 20664267.
15. Gallagher AM, Setakis E, Plumb JM, Clemens A, van Staa TP. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb Haemost. 2011; 106: 968-977. doi:10.1160/TH11-05-0353 PMID: 21901239.
16. Wan Y, Heneghan C, Perera R, Roberts N, Hollowell J, Glasziou P, et al. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: A systematic review. Circ Cardiovasc Qual Outcomes 2008; 1: 84-91. doi:10.1161/CIRCOUTCOMES.108.796185 PMID: 20031794.
17. De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F, et al. New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper. J Am Coll Cardiol. 2012; 59: 1413-1425. doi:10.1016/j.jacc.2012.02.008 PMID: 22497820.
18. Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: An analysis of the RE-LY trial. Lancet. 2010; 376: 975-983. doi:10.1016/S0140-6736(10)61194-4 PMID: 20801496.
19. Guo Y, Pisters R, Apostolakis S, Blann AD, Wang H, Zhao X, et al. Stroke risk and suboptimal thromboprophylaxis in Chinese patients with atrial fibrillation: Would the novel oral anticoagulants have an impact? Int J Cardiol. 2013; 168: 515-522. doi:10.1016/j.ijcard.2012.09.187 PMID: 23103146.
20. Tsai WC, Chen CY, Kuo HF, Wu MT, Tang WH, Chu CS, et al. Areca nut chewing and risk of atrial fibrillation in Taiwanese men: A nationwide ecological study. Int J Med Sci. 2013; 10: 804-811. doi:10.7150/ijms.5998 PMID: 23794944.
21. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007; 146: 857-867. PMID: 17577005.
22. Friberg L, Rosenqvist M, Lip GY. Net clinical benefit of warfarin in patients with atrial fibrillation: A report from the Swedish atrial fibrillation cohort study. Circulation. 2012; 125: 2298-2307. doi:10.1161/CIRCULATIONAHA.111.055079 PMID: 22514252.
23. Olesen JB, Lip GY, Lindhardsen J, Lane DA, Ahlehoff O, Hansen ML, et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a 'real world' nationwide cohort study. Thromb Haemost. 2011; 106: 739-749. doi:10.1160/TH11-05-0364 PMID: 21789337.
24. Singer DE, Chang Y, Fang MC, Borowsky LH, Pomernacki NK, Udaltsova N, et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med. 2009; 151: 297-305. PMID: 19721017.
25. Gomes T, Mamdani MM, Holbrook AM, Paterson JM, Hellings C, Juurlink DN. Rates of hemorrhage during warfarin therapy for atrial fibrillation. CMAJ. 2013; 185: E121-E127. doi:10.1503/cmaj.121218 PMID: 23184840.
26. Roldán V, Marín F, Manzano-Fernández S, Gallego P, Vílchez JA, Valdés M. The HAS-BLED score has better prediction accuracy for major bleeding than the CHADS or CHADS-VASc scores In anticoagulated patients with atrial fibrillation. J Am Coll Cardiol. 2013; 62:2199-204. doi:10.1016/j.jacc.2013.08.1623 PMID: 24055744.
27. Apostolakis S, Lane DA, Buller H, Lip GY. Comparison of the CHADS2, CHA2DS2-VASc and HASBLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with atrial fibrillation: The AMADEUS trial. Thromb Haemost. 2013; 110: 1074-1075. doi:10.1160/TH13-07-0552 PMID: 24048467.
28. Shen AY, Yao JF, Brar SS, Jorgensen MB, Chen W. Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. J Am Coll Cardiol. 2007; 50: 309-315. PMID: 17659197.
29. Hori M, Connolly SJ, Zhu J, Liu LS, Lau CP, Pais P, et al. Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation. Stroke. 2013; 44: 1891-1896. doi:10.1161/STROKEAHA.113.000990 PMID: 23743976.
30. Morgan CL, McEwan P, Tukiendorf A, Robinson PA, Clemens A, Plumb JM. Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control. Thromb Res. 2009; 124: 37-41. doi:10.1016/j.thromres.2008.09.016 PMID: 19062079.
31. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012; 33: 2719-2747. doi:10.1093/eurheartj/ehs253 PMID: 22922413.
32. Wallentin L, Becker RC, James SK, Harrington RA. The PLATO trial reveals further opportunities to improve outcomes in patients with acute coronary syndrome. Editorial on Serebruany. "Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified" (Thromb Haemost 2011; 105.5). Thromb Haemost. 2011; 105: 760-762. doi:10.1160/TH11-03-0162 PMID: 21394383.
33. Ogawa S, Aonuma K, Tse H-F, Huang D, Huang J-L, Kalman J, et al. The APHRS's 2013 statement on antithrombotic therapy of patients with nonvalvular atrial fibrillation. Journal of Arrhythmia. 2013; 29: 190-200.
34. Wong RS, Cheng G, Chan TY. Use of herbal medicines by patients receiving warfarin. Drug Saf. 2003; 26: 585-588. PMID: 12825970.
35. Chao TF, Liu CJ, Chen SJ, Wang KL, Lin YJ, Chang SL, et al. Atrial Fibrillation and the Risk of Ischemic Stroke. Stroke. 2012; 43: 2551-2555. PMID: 22871677.
36. Lip GY, Rasmussen LH, Skjoth F, Overvad K, Larsen TB. Stroke and mortality in patients with incident heart failure: The Diet, Cancer and Health (DCH) cohort study. BMJ Open. 2012; 2.